INR 58.75
(1.93%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 59.67 Million INR | -43.54% |
2022 | 286.66 Million INR | 65.61% |
2021 | 173.1 Million INR | -3.08% |
2020 | 178.59 Million INR | 26.27% |
2019 | 141.43 Million INR | 27.46% |
2018 | 110.96 Million INR | 7.34% |
2017 | 103.37 Million INR | 0.92% |
2016 | 102.43 Million INR | -7.42% |
2015 | 110.64 Million INR | 9.5% |
2014 | 101.05 Million INR | 13.92% |
2013 | 88.7 Million INR | 71.81% |
2012 | 51.62 Million INR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 44.9 Million INR | -8.8% |
2023 Q1 | 58.47 Million INR | 13.49% |
2023 Q2 | 59.07 Million INR | 1.02% |
2023 Q4 | 49.23 Million INR | 30.78% |
2023 FY | 161.84 Million INR | -43.54% |
2023 Q3 | 37.64 Million INR | -36.27% |
2022 Q4 | 51.52 Million INR | -34.63% |
2022 Q1 | 75.58 Million INR | 316.02% |
2022 Q2 | 80.74 Million INR | 6.83% |
2022 Q3 | 78.81 Million INR | -2.39% |
2022 FY | 286.66 Million INR | 65.61% |
2021 Q2 | 80.24 Million INR | 62.88% |
2021 Q4 | -34.99 Million INR | -144.47% |
2021 Q1 | 49.26 Million INR | -8.53% |
2021 FY | 173.1 Million INR | -3.08% |
2021 Q3 | 78.67 Million INR | -1.96% |
2020 FY | 178.59 Million INR | 26.27% |
2020 Q2 | 70.44 Million INR | 0.0% |
2020 Q3 | 53.86 Million INR | -23.54% |
2020 Q4 | 53.86 Million INR | 0.0% |
2020 Q1 | 70.44 Million INR | 55.45% |
2019 Q4 | 45.31 Million INR | 0.0% |
2019 FY | 141.43 Million INR | 27.46% |
2019 Q2 | 42.81 Million INR | 0.0% |
2019 Q1 | 42.81 Million INR | 0.94% |
2019 Q3 | 45.31 Million INR | 5.84% |
2018 Q4 | 42.41 Million INR | 0.0% |
2018 FY | 110.96 Million INR | 7.34% |
2018 Q3 | 42.41 Million INR | 27.37% |
2018 Q2 | 33.3 Million INR | 0.0% |
2018 Q1 | 33.3 Million INR | -5.8% |
2017 Q3 | 35.35 Million INR | 3.51% |
2017 Q4 | 35.35 Million INR | 0.0% |
2017 FY | 103.37 Million INR | 0.92% |
2017 Q1 | 34.15 Million INR | 0.0% |
2017 Q2 | 34.15 Million INR | 0.0% |
2016 FY | 102.43 Million INR | -7.42% |
2015 FY | 110.64 Million INR | 9.5% |
2014 FY | 101.05 Million INR | 13.92% |
2013 FY | 88.7 Million INR | 71.81% |
2012 FY | 51.62 Million INR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Alembic Pharmaceuticals Limited | 15.86 Billion INR | 99.624% |
Hester Biosciences Limited | 908.84 Million INR | 93.434% |
Aarti Drugs Limited | 1.16 Billion INR | 94.889% |
Aarti Pharmalabs Limited | 3.07 Billion INR | 98.059% |
Albert David Limited | 1.02 Billion INR | 94.185% |
Alembic Limited | 872.45 Million INR | 93.16% |
Alkem Laboratories Limited | 32.83 Billion INR | 99.818% |
Bafna Pharmaceuticals Limited | 455.58 Million INR | 86.901% |
Bajaj HealthCare Limited | 985.34 Million INR | 93.944% |
Biofil Chemicals and Pharmaceuticals Limited | 6.82 Million INR | -775.0% |
Brooks Laboratories Limited | 51.18 Million INR | -16.598% |
Eris Lifesciences Limited | 4.94 Billion INR | 98.793% |
FDC Limited | 3.49 Billion INR | 98.295% |
Glenmark Life Sciences Limited | 11.64 Billion INR | 99.487% |
Gufic Biosciences Limited | 1.18 Billion INR | 94.971% |
Hikal Limited | 4.46 Billion INR | 98.663% |
Ind-Swift Limited | 946.56 Million INR | 93.696% |
Innova Captab Limited | 931.03 Million INR | 93.59% |
IOL Chemicals and Pharmaceuticals Limited | 2.2 Billion INR | 97.289% |
Jagsonpal Pharmaceuticals Limited | 438.55 Million INR | 86.393% |
Jubilant Pharmova Limited | 14.45 Billion INR | 99.587% |
Lincoln Pharmaceuticals Limited | 1.07 Billion INR | 94.445% |
Lupin Limited | 125.09 Billion INR | 99.952% |
Mangalam Drugs & Organics Limited | 162.22 Million INR | 63.215% |
Morepen Laboratories Limited | 1.98 Billion INR | 96.997% |
Nectar Lifesciences Limited | 932.7 Million INR | 93.602% |
Orchid Pharma Limited | 800.77 Million INR | 92.548% |
Procter & Gamble Health Limited | 2.99 Billion INR | 98.008% |
RPG Life Sciences Limited | 1.63 Billion INR | 96.351% |
Kilitch Drugs (India) Limited | 412.42 Million INR | 85.531% |
Sigachi Industries Limited | 579.88 Million INR | 89.709% |
Solara Active Pharma Sciences Limited | 2.55 Billion INR | 97.664% |
Suven Pharmaceuticals Limited | 1.4 Billion INR | 95.746% |
Themis Medicare Limited | 1.12 Billion INR | 94.699% |
Unichem Laboratories Limited | 6.72 Billion INR | 99.113% |
Vaishali Pharma Limited | 84.02 Million INR | 28.983% |
Wanbury Limited | 978.96 Million INR | 93.904% |
Windlas Biotech Limited | 1 Billion INR | 94.071% |
ZIM Laboratories Limited | 1.01 Billion INR | 94.109% |
Ind-Swift Laboratories Limited | 2.12 Billion INR | 97.191% |
Ipca Laboratories Limited | 18.98 Billion INR | 99.686% |
Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.961% |
Venus Remedies Limited | 1.91 Billion INR | 96.886% |
Sakar Healthcare Limited | 204.07 Million INR | 70.759% |
Aurobindo Pharma Limited | 55.65 Billion INR | 99.893% |
Divi's Laboratories Limited | 14.17 Billion INR | 99.579% |
AstraZeneca Pharma India Limited | 2.47 Billion INR | 97.587% |
Mankind Pharma Limited | 29.27 Billion INR | 99.796% |
Sequent Scientific Limited | 2.9 Billion INR | 97.944% |
Laurus Labs Limited | 11.9 Billion INR | 99.499% |
Neuland Laboratories Limited | 2.92 Billion INR | 97.963% |
J. B. Chemicals & Pharmaceuticals Limited | 14.79 Billion INR | 99.597% |
Glenmark Pharmaceuticals Limited | 46.95 Billion INR | 99.873% |
Zydus Lifesciences Limited | 125.21 Billion INR | 99.952% |
Amrutanjan Health Care Limited | 2.09 Billion INR | 97.15% |
Wockhardt Limited | 8.48 Billion INR | 99.296% |
Bal Pharma Limited | 555.62 Million INR | 89.26% |
Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.938% |
Bliss GVS Pharma Limited | 1.41 Billion INR | 95.795% |
Par Drugs and Chemicals Limited | 58.28 Million INR | -2.38% |
Caplin Point Laboratories Limited | 2.17 Billion INR | 97.256% |
Shilpa Medicare Limited | 3.33 Billion INR | 98.21% |
Valiant Laboratories Limited | 138.02 Million INR | 56.766% |
Ajanta Pharma Limited | 30.46 Billion INR | 99.804% |
Aarey Drugs & Pharmaceuticals Limited | 14.21 Million INR | -319.862% |
Granules India Limited | 10.31 Billion INR | 99.421% |
Medicamen Biotech Limited | 335.16 Million INR | 82.195% |
Syncom Formulations (India) Limited | 345.63 Million INR | 82.735% |
Piramal Enterprises Limited | 63.65 Billion INR | 99.906% |
Torrent Pharmaceuticals Limited | 21.42 Billion INR | 99.721% |
NATCO Pharma Limited | 10.05 Billion INR | 99.407% |
Suven Life Sciences Limited | 109.75 Million INR | 45.626% |
Krebs Biochemicals & Industries Limited | 46.15 Million INR | -29.29% |
Strides Pharma Science Limited | 9.16 Billion INR | 99.349% |
Indoco Remedies Limited | 12.06 Billion INR | 99.505% |
Alpa Laboratories Limited | 127.38 Million INR | 53.152% |
Lasa Supergenerics Limited | 291.17 Million INR | 79.505% |
Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 98.06% |